Related Experiment Video

Updated: May 10, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K

Targeting FGFR3 gain-of-function with Infigratinib, a promising precision therapy for Hypochondroplasia

Antonella Forlino1

  • 1University of Pavia, Molecular Medicine.

Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|September 6, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Experiment Videos

Last Updated: May 10, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.3K
Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

7.8K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Articles linked to this work by shared authors, journal, and citation graph.

Infectious seeds of valve calcification: Exploring the bacterial hypothesis in the pathogenesis of calcific aortic valve disease.

European journal of clinical investigation·2026

Molecular drivers of osteogenesis imperfecta: a cellular and extracellular collagen disease.

Clinical science (London, England : 1979)·2025

The Role of Osteoblasts in Phenotypic Variability of Dominant Osteogenesis Imperfecta: Evidence from Patients and Murine Models.

International journal of molecular sciences·2025

Combined antiresorptive and new anabolic drug approach in osteogenesis imperfecta zebrafish models.

JBMR plus·2025

Bone and Hemophilia: The Role of Factor VIII-Systematic Review.

International journal of molecular sciences·2025

Cant1 Affects Cartilage Proteoglycan Properties: Aggrecan and Decorin Characterization in a Mouse Model of Desbuquois Dysplasia Type 1.

Biomolecules·2024

Deciphering the development of synovial joints in the limbs: Recent discoveries and clinical implications.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Lesion Expansion in Craniofacial Fibrous Dysplasia: Natural History and Indicators of Progression in the Frontal, Zygomatic, and Sphenoid Bones.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Genotype-First Characterization of Familial Hypocalciuric Hypercalcemia Type 1: Prevalence, Serum Calcium and Clinical Associations.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Identification of a novel small-molecule modulator targeting SNX10 to inhibit osteoclastic bone resorption.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Osteosarcopenia Revisited: From Mechanisms to Management.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Multimorbidity Double Burden: Elevated Refracture Risk Despite High Mortality Following Fractures - A Linked Cohort Study.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Deficiency of GLUT1 in macrophages reprograms tumor-associated macrophages to normalize tumor vasculature and retards the progression of tumors.

International journal of biological sciences·2026

A proposal of good manufacturing practices (GMP) laboratory for CAR T-cell therapy in Latin America and the Caribbean: challenges and opportunities.

Frontiers in public health·2026

In vivo selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft model.

NAR cancer·2026

From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma.

Frontiers in immunology·2026

Doravirine and islatravir for HIV-1 treatment: A systematic review and meta-analysis with GRADE assessment.

Therapeutic advances in infectious disease·2026

Advancement in Inflammation-responsive Drug Delivery System for Chronic Inflammation.

Anti-inflammatory & anti-allergy agents in medicinal chemistry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us